DRG Market Assessment 보고서
질환 개요 및 예측, 역학 인텔리전스, 바이오시밀러 인텔리전스, China In-depth 등 폭넓은 시장 인텔리전스를 확인해 보세요.
Multiple Sclerosis | Emerging Therapies | Lemtrada (alemtuzumab) | US | Wave 3 | 2015
LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Lemtrada, a potent, intravenous disease-modifying therapy (DMT) approved to treat…
Diabetic Macular Edema (The Impact of Costly Market Entrants for Diabetic Macular Edema) | Physician & Payer Forum | US | 2015
How Are U.S. Ophthalmologists Incorporating Newly Approved Products into the Treatment Algorithm and How Receptive Are Payers to These Agents? Until the U.S. approval of Genentech’s Lucentis…
Biosimilars Advisory Service : Acceptance of Biosimilars Across Physician Specialties | US,France and Germany | 2015
Gaining physician confidence is critical to securing a meaningful position in developed markets; therefore, understanding their concerns about biosimilar products should be an important part of…